Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 325412, 7 pages
http://dx.doi.org/10.1155/2013/325412
Research Article

Immunomodulatory Effect of Bisphosphonate Risedronate Sodium on CD163+ Arginase 1+ M2 Macrophages: The Development of a Possible Supportive Therapy for Angiosarcoma

Department of Dermatology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai 980-8574, Japan

Received 31 July 2013; Revised 16 October 2013; Accepted 30 October 2013

Academic Editor: Gianluca Matteoli

Copyright © 2013 Taku Fujimura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Sasaki, T. Soejima, K. Kishi et al., “Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome,” International Journal of Radiation Oncology, Biology, Physics, vol. 52, no. 4, pp. 1032–1040, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. J. R. Ward, S. J. Feigenberg, N. P. Mendenhall, R. B. Marcus Jr., and W. M. Mendenhall, “Radiation therapy for angiosarcoma,” Head and Neck, vol. 25, no. 10, pp. 873–878, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. B. F. Koontz, E. F. Miles, M. A. D. Rubio et al., “Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies,” Head and Neck, vol. 30, no. 2, pp. 262–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Ishibashi, T. Fujimura, A. Hashimoto et al., “Successful treatment of MMP9-expressing angiosarcoma with low-dose docetaxel and biphosphonate,” Case Reports in Dermatology, vol. 4, pp. 5–9, 2012. View at Google Scholar
  5. Y. Kambayashi, T. Fujimura, S. Furudate, A. Hashimoto, T. Haga, and S. Aiba, “Comparison of immunosuppressive cells and cytotoxic cells in angiosarcoma: the development of a possible supportive therapy for angiosarcoma,” Dermatology, vol. 227, pp. 14–20, 2013. View at Google Scholar
  6. Y. Kambayashi, T. Fujimura, and S. Aiba, “Comparison of immunosuppressive cells and immunomodulatory cells in kerartoacanthoma and invasive squamous cell carcinoma,” Acta Dermato-Venereologica, vol. 93, no. 6, pp. 663–668, 2013. View at Publisher · View at Google Scholar
  7. J. R. Groom and A. D. Luster, “CXCR3 ligands: redundant, collaborative and antagonistic functions,” Immunology and Cell Biology, vol. 89, no. 2, pp. 207–215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Chen, Y. Yao, C. Gong et al., “CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3,” Cancer Cell, vol. 19, no. 4, pp. 541–555, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Plönes, A. Krohn, M. Burger et al., “Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas,” PLoS ONE, vol. 7, Article ID e41746, 2012. View at Google Scholar
  10. T. Miyagaki, M. Sugaya, H. Suga et al., “Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis,” Journal of the European Academy of Dermatology and Venereology, vol. 27, no. 1, pp. e60–e67, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Nagano, Y. Yamada, T. Ikeda, H. Kanki, T. Kamo, and C. Nishigori, “Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients,” Cancer, vol. 110, no. 3, pp. 648–651, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Heymann, B. Ory, F. Gouin, J. R. Green, and F. Rédini, “Bisphosphonates: new therapeutic agents for the treatment of bone tumors,” Trends in Molecular Medicine, vol. 10, no. 7, pp. 337–343, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Fujimura, S. Furudate, Y. Kambayashi, and S. Aiba, “Potential use of bisphosphonates in invasive extramammary Paget's disease: an immunohistochemical investigation,” Clinical and Developmental Immunology, vol. 2013, Article ID 164982, 6 pages, 2013. View at Publisher · View at Google Scholar
  14. S. P. Jagdev, R. E. Coleman, C. M. Shipman, A. Rostami-H, and P. I. Croucher, “The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel,” British Journal of Cancer, vol. 84, no. 8, pp. 1126–1134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Fehm, M. Zwirner, D. Wallwiener, H. Seeger, and H. Neubauer, “Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay,” BMC Cancer, vol. 12, article 308, 2012. View at Google Scholar
  16. C. Melani, S. Sangaletti, F. M. Barazzetta, Z. Werb, and M. P. Colombo, “Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma,” Cancer Research, vol. 67, no. 23, pp. 11438–11446, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. K. N. Kodumudi, K. Woan, D. L. Gilvary, E. Sahakian, S. Wei, and J. Y. Djeu, “A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers,” Clinical Cancer Research, vol. 16, no. 18, pp. 4583–4594, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Vogel and E. M. Marcotte, “Insights into the regulation of protein abundance from proteomic and transcriptomic analyses,” Nature Reviews Genetics, vol. 13, no. 4, pp. 227–232, 2012. View at Publisher · View at Google Scholar · View at Scopus